Diffuse gliomas are composed of cells of astrocytic and oligodendrocytic phenotype ([Louis *et al*, 2001](#bib24){ref-type="other"}). Accordingly, the main types of diffuse gliomas (referred to hereafter as to 'gliomas') are astrocytomas (*As*), oligodendrogliomas (*Ols*), and mixed oligoastrocytomas (*OlAs*) ([Kleihues *et al*, 2002](#bib21){ref-type="other"}). Malignancy of gliomas is assessed by histological grades (II--IV) depending on the presence of cellular pleomorphism, mitosis, vascular proliferation, and necrosis ([Kleihues *et al*, 2002](#bib21){ref-type="other"}). The most malignant grade IV tumours, multiform glioblastomas (*GBMs*), are associated with a median survival of less than 12 months. Even grade II gliomas, however, are ultimately lethal, because of relentless progression to higher grade. Importantly, local treatments of tumours of all grades fail because gliomas are highly invasive ([Giese *et al*, 2003](#bib11){ref-type="other"}). Thus, surgery fails since the tumour recurs inevitably at the infiltrated margin, no matter how much margin has been resected ([Chicoine and Silbergeld, 1995](#bib3){ref-type="other"}; [Silbergeld and Chicoine, 1997](#bib32){ref-type="other"}).

Since invasiveness is largely responsible for the dismal outcome of glioma patients, its cellular and molecular mechanisms ([Giese *et al*, 2003](#bib11){ref-type="other"}) and kinetics ([Burgess *et al*, 1997](#bib2){ref-type="other"}) have been intensively studied. From a kinetic point of view, glioma invasion of the brain is defined as a major determinant of glioma growth ([Burgess *et al*, 1997](#bib2){ref-type="other"}; [Swanson *et al*, 2000](#bib33){ref-type="other"}, [2002](#bib34){ref-type="other"}). Glioma growth involves two independent determinants: infiltrative, resulting from tumour cell spread in the brain parenchyma, and *in situ* proliferative, the net result of cell division and apoptosis ([Burgess *et al*, 1997](#bib2){ref-type="other"}).

Although highly desirable as a basis to assess the infiltrative growth potential of glioma biopsies ([Burgess *et al*, 1997](#bib2){ref-type="other"}), data on glioma invasiveness in primary culture are scarce (for a review, see [De Boüard *et al*, 2002](#bib4){ref-type="other"}). This is particularly true for grade II and III gliomas, of which less than 25 cases have been studied ([De Boüard *et al*, 2002](#bib4){ref-type="other"}). Results from these studies, obtained with different invasion assays, are often contradictory. Moreover, it is now admitted that some of these assays fail to mimic the *in vivo* environment of gliomas, and probably provide biased estimates of invasiveness ([Jung *et al*, 2001](#bib17){ref-type="other"}; [De Boüard *et al*, 2002](#bib4){ref-type="other"}). We developed, on the basis of techniques recently described using glioma cell lines ([Jung *et al*, 2001](#bib17){ref-type="other"}; [Murakami *et al*, 2001](#bib27){ref-type="other"}), an assay wherein glioma biopsy fragments are implanted into rodent brain slices ([De Boüard *et al*, 2002](#bib4){ref-type="other"}). This organotypic assay, in which invasive glioma cells show patterns of dissemination and phenotypes similar to those *in vivo*, also allows studying quantitatively the invasive potential of gliomas of different types and grades.

In this study, we assessed the *ex vivo* invasive potentials of 42 glioma biopsy specimens and explored by multivariate analysis their relationships with established parameters of glioma prognosis, such as histological type and grade, presence or absence of deletions on chromosomes 1p and 19q ([Louis *et al*, 2001](#bib24){ref-type="other"}), tumour cell proliferation and apoptosis ([Rhodes, 1998](#bib28){ref-type="other"}), vascularisation, and cell density ([McKeown and Ramsay, 1996](#bib26){ref-type="other"}). The main result of this analysis is that Ols and mixed OlAs are less invasive than purely astrocytic tumours of similar malignancy grade. In Discussion, we offer a perspective on glioma invasion, emphasising its interplay with *in situ* proliferation and the potential consequences of this interplay for glioma growth.

MATERIAL AND METHODS
====================

The analysis included biopsies from 51 patients (42 grade II--IV gliomas, two grade I gangliogliomas, a choroid plexus papilloma, two meningiomas, two squamous-cell lung carcinoma brain metastases, and two gliosis specimens associated with primary vasculitis of the brain and an arachnoid cyst). One biopsy fragment was processed for cell culture as described below, and a second one was submitted for histopathological analysis. Quantification of 1p/19q status, histological features, cell proliferation, and apoptosis was carried out on paraffin sections of the second fragment.

Histological classification of gliomas
--------------------------------------

Gliomas were classified by the guidelines of the WHO 2000 classification ([Kleihues *et al*, 2002](#bib21){ref-type="other"}). Mixed OlAs were tumours in which the two cell populations with oligo- and astroglial phenotype were topographically separated, at least in some areas ([Bigner *et al*, 1999](#bib1){ref-type="other"}); this definition basically corresponds to the biphasic OlAs in the WHO 2000 classification. Glioblastomas with oligodendroglial component (*GOCs*) ([Bigner *et al*, 1999](#bib1){ref-type="other"}; [Kleihues *et al*, 2002](#bib21){ref-type="other"}) were biphasic tumours with grade IV histological features.

Slides were first examined separately by three pathologists (CC, FC, and RG), and then in several sessions using a multi-head microscope, until a consensus diagnosis was reached.

Immunohistochemistry
--------------------

The following primary monoclonal (MC) and polyclonal (PC) antibodies were applied (12--16 h at 4°C) to deparaffinised 5 *μ*m sections of neutral formalin-fixed specimens, with or without antigen retrieval (AR) (microwave treatment (3 × 5 min) in citrate buffer (pH 6.0)): anti-GFAP (PC, 1 : 100, Dako, Glostrup, Denmark), anti-Ki67 (MIB-1) (MC, 1 : 50, Immunotech, Marseilles, France) (AR), anti-active human caspase 3 (PC, 1 : 2000, R & D Systems, Abingdon, UK) (AR), and anti-CD34 (MC, 1 : 200) (Dako). Bound primary antibodies were detected by a Vector Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) following the manufacturer\'s instructions with DAB as the chromogen and haematoxylin counterstain. The anti-caspase 3 antibody was detected by an FITC-conjugated secondary antibody (1 : 500, Jackson ImmunoResearch, Philadelphia, PA, USA), and slides were counterstained with DAPI (10 *μ*g ml^−1^). Negative controls had the primary antibody omitted. In 13 cases, apoptosis was also detected by an ApopTag® kit (Intergen, Purchase, NY, USA) according to the manufacturer\'s instructions. Values of caspase 3 and ApopTag® labeling indices (LIs), determined as outlined below, were concordant (1.8±1.7 *vs* 1.9±1.6%) and tended to be positively correlated (*ρ*=0.56, *P*=0.053). Owing to high variability of nuclear staining intensity with ApopTag® ([Rhodes, 1998](#bib28){ref-type="other"}), the more easy-to-read caspase 3 immunolabelling was preferred ([Figure 1A, B](#fig1){ref-type="fig"}Figure 1Nuclear (**A**) and cytoplasmic (**B**) active caspase 3 immunolabellings. For the purposes of this illustration, bound anti-caspase 3 primary antibody was detected by a biotinylated secondary antibody, an avidin--peroxidase complex (both from Vector), and the TSA cyanine 3 signal amplification system (PerkinElmer™, Boston, USA). Separately acquired images in the red and blue (DAPI) channels were subjected to a shading correction by subtracting from the original image its version blurred by a 50-fold application of a 46-size lowpass filter, and mildly deconvoluted using the iterative optical deconvolution module of KS400 3.0 with 10 itinerations of a maximum likelihood algorithm and suitable aperture values. 1p/1c (**C,D**) and 19q (**E,F**) showing representative fields of tumours without (**C,E**) and with (**D,F**) chromosomal losses. Note that, for the simultaneous identification of two probes (e.g. 1p/1c), nine patterns of labelling ranging from (0,0) to (2,2) are possible. All except (2,2) can be due to nuclear truncation. We attempted to control for these inevitable artefacts by applying the two methods outlined in [Figure 2](#fig2){ref-type="fig"}. To cut cytoplasmic background staining and to safely overamplify probe signals, FISH images represent field reconstructions of nuclei projected upon an artificial black background.).

Quantitative analysis of proliferation, apoptosis, and histological features
----------------------------------------------------------------------------

All quantitative analyses were carried out using different modules of the KS400 3.0 image analysis software (Zeiss, Germany) on microscopic images digitised with a Coolsnap 300 camera (Roper Scientific, Tucson, AZ, USA) coupled to an Axioplan 2 microscope (Zeiss).

On histological sections, the Ki-67 (MIB-1) and active caspase 3 LIs ([Schiffer *et al*, 2001](#bib31){ref-type="other"}), and tumour cell densities (cells mm^−2^) were estimated in 10--15 microscopic fields (× 400) (at least 1000 tumour cells) in a representative tumour zone. The proliferation/apoptosis (MIB1/caspase 3) ratios assessing the *in situ* growth potential of a glioma ([Rhodes, 1998](#bib28){ref-type="other"}) were calculated for 37 tumours. Vessel density was evaluated on CD34-immunostained sections by image analysis ([Guillamo *et al*, 2001](#bib13){ref-type="other"}). Compact tumour areas (\>90% of tumour cells) and diffuse areas where tumour cells intermingled with host cells were interactively marked in the image graphics plane and their respective proportions calculated.

Fluorescence *in situ* hybridisation (FISH) for 1p and 19q
----------------------------------------------------------

Dual-probe FISH on 5 *μ*m paraffin sections (39 gliomas and four brain specimens free of tumour) was carried out with differentially labelled probes for 1p36 (D1S32), centromere 1 (1c) (pUC1.77); all specimens with 1p loss were subsequently tested with a locus-specific probe for 19q13 (BAC2310A1). FISH was performed as previously described with modifications ([Van den Bent *et al*, 2003](#bib36){ref-type="other"}). Briefly, probes were nick-labelled with biotin-16-dUTP or digoxigenin-11-dUTP (Roche Diagnostics, Almere, The Netherlands). Deparaffinised sections (4 *μ*m) were microwave-treated (5 min) in citrate buffer (pH 6.0), digested with pepsin solution (Sigma) (0.005% in 0.1 [M]{.smallcaps} NaCl, pH 1.5) (20 min) at 37°C, dehydrated in alcohols (70, 90, and 100%), and air-dried. The probes were applied to the slides, and probes and specimen DNA were simultaneously denatured at 80°C (3 min). Hybridisation was carried out overnight (BAC2310A1) or over 48 h (D1S32 and pUC1.77). Following washes in 1.5 [M]{.smallcaps} urea/0.1 × SSC at 45°C (15 min) and in Tween 0.1%/2 × SSC (5 min), slides were exposed to a FITC-conjugated sheep antibody (1 : 50) and Cy3-conjugated avidin (1 : 100) (Roche Diagnostics) in PBS at 37°C (20 min), washed twice in Tween 0.1%/2 × SSC, counterstained with DAPI, and mounted in antifade solution. Signals (60--100 nonoverlapping nuclei per specimen) were counted on a Leica DM RXA microscope equipped with single- or triple-pass filtres (DAPI/FITC/Cy3) ([Figure 1C-F](#fig1){ref-type="fig"}). 1p/19q loss was evaluated by two methods adapted to eliminate errors due to sectioning of nuclei. The mean 1p/1c signal ratio (*x*~1p/1c~) of the nontumour specimens was calculated. Tumours with ratios less than *x*~1p/1c~-3SD were considered abnormal ([Figure 2A](#fig2){ref-type="fig"}Figure 2(**A**) 1p loss (1c: centromeric probe) in 39 gliomas: tumours with 1p/1c values below the mean--3s.d. threshold were considered to have 1p loss. Tumours with ratios below this threshold not marked with an asterisk (^\*^) also had 19q loss. 1p loss was detected in 12 out of 19 oligodendroglial and in one out of 20 astrocytic tumours (*P*\<0.0003); 1p/19q loss in nine out of 19 oligodendroglial and in zero out of 20 astrocytic tumours (*P*\<0.0006). Four normal brain specimens were used to calculate the threshold. An example of a grade II *Ol* with a 1p/19q loss estimated by comparison of 1p signals with 1c signals in the same specimen (**B**), or of 19q signals with the mean 19q signal counts in the control group (**C**) (Kolmogorov--Smirnov test).). Additionally, for each specimen, the cumulative counts of 1p and 1c (reference) signals were compared by the Kolmogorov--Smirnov test ([Figure 2B](#fig2){ref-type="fig"}). These two methods yielded identical results. To estimate 19q loss, for which no reference probe was available, the cumulative signal count of each tumour was compared with the mean cumulative count of the nontumour specimens ([Figure 2C](#fig2){ref-type="fig"}).

*In vitro* invasion assay
-------------------------

The invasion assay was performed as previously described ([De Boüard *et al*, 2002](#bib4){ref-type="other"}). Briefly, 400 *μ*m coronal slices cut from the brains of 7-days-old C57/bl6 mice were deposited onto Millicell-CM membranes (Millipore, France) and maintained above 1 ml of medium (minimum essential medium (MEM) (Gibco, France), 1 g l^−1^ [D]{.smallcaps}-glucose, 10% foetal calf serum, 0.1 g l^−1^ transferrin, 16 *μ*g l^−1^ putrescin, 40 *μ*g l^−1^ *N*-selenium, 30 *μ*g l^−1^ tri-iodothyronin, 5 mg l^−1^ insulin, and 60 *μ*g l^−1^ progesterone) in a standard cell incubator. Fragments (0.1--0.4 mm) containing histologically verified viable tumour tissue were incubated in 30 *μ*g ml^−1^ DiI (1,1′-dioctadeccyl-3,3,3′,3′,-tetramethylindocarbocyanine perchlorate) (Molecular Probes, Eugene, OR, USA) for 24 h and implanted in the thickness of the slice. A median of 10 (2--16) slice cultures was studied per case. At 15 days post culture, slices were fixed in 4% paraformaldehyde (4 h at 4°C), removed from the filtre membrane, and mounted in antifade medium Fluoromount G, (Interchim, France). Animal studies were carried out in accordance with institutional guidelines for the care, and in agreement with the general recommmendations of the [UKCCCR Guidelines for the Welfare of Experimental Animals (1998)](#bib35){ref-type="other"}.

Quantitative analysis of distance and cell density of invasion
--------------------------------------------------------------

Distances of invasion of individual cells from the implant margin ([Figure 3](#fig3){ref-type="fig"}Figure 3Examples of an invasive (**A**) and a practically noninvasive (**B**) tumour in a brain slice. Each of the two image montages is composed of six contiguous microscopic fields (× 100, 0.76 mm^2^). To avoid out-of-focus fluorescent glow and to facilitate tumour cell recognition, each image of glioma cells was separately segmented using grey morphology and adaptive thresholding algorithms (KS400 3.0), and the resulting binary image was overlaid in grey.) were measured in the point measurement mode of KS 400 3.0. In each case, the maximal distance of invasion (*D*~90~) was assessed by the 90th percentile calculated from the distribution of all invasive cells (median *n*=1923, range: 257--4766 for GBMs, *n*=396, range: 48--1215 for grade II and III gliomas).

The maximal cell density of invasion as a function of the invasion distance (*C*~90~) was assessed by first calculating the 90th percentile of the density of invading cell (cells mm^−2^) at every 100 *μ*m increment of migration distance. Then, *C*~90~ of each tumour was calculated in arbitrary units (AU) as the area under the curve of maximal cell densities of invasion. *D*~90~, assessing the outer boundary of invasive cell spread, and *C*~90~, assessing the maximal number of invading cells per unit area, are obviously two complementary characteristics of invasion ([Figure 4](#fig4){ref-type="fig"}Figure 4Representative examples of the three patterns of maximal cell density of invasion (*C*~90~) in grade IV tumours: high (200⩽*C*~90~⩽400 cells mm^−2^), intermediate (100⩽*C*~90~⩽200 cells mm^−2^), and low (*C*~90~⩽100 cells mm^−2^) within 0.5 mm from the implants. These three tumours showed comparable maximal distance of invasion (*D*~90~), but important differences in *C*~90~: D90 and C90 are two complementary estimates of invasion.).

Statistics
----------

Statistical analysis was performed using StatView F-4.11 (Abacus Concepts, Berkeley, CA, USA) and GraphPad 3.00 (GraphPad Software, San Diego, CA, USA). Two groups were compared by the Mann--Whitney test and three groups by the Kruskall--Walis test. Correlations were evaluated by the Spearman test (*ρ*), correlation analysis (*r*), or the Fisher exact test. Principal component analysis (PCA) was used to illustrate the relationship between invasion, 1p/19q loss, *in situ* growth, and several quantitatively evaluated histological features in grade II and III gliomas. Principal component analysis summarises information contained in many correlated variables as a few uncorrelated factors (principle components), thus facilitating the comprehension of complex relationships ([McKeown and Ramsay, 1996](#bib26){ref-type="other"}). Using standard techniques (StatView F-4.11), the number of factors extracted was set to account for more than 80% of data variation and axes were rotated by a Varimax/Orthotran transformation. Data in the text are presented either as mean±standard deviation, or as median (range).

RESULTS
=======

Tumour histology and 1p/19q status
----------------------------------

We examined 21 grade IV (14 purely astrocytic GBMs, six GOCs, one giant-cell GBM) and 21 grade II and III gliomas (As: grade II, *n*=4, grade III, *n*=4; Ols: grade II, *n*=4, grade III, *n*=6; OlAs: grade II, *n*=1, grade III, *n*=2). FISH was successfully carried out on 39 grade II--IV tumours. In these 39 tumours, and in the subgroup of grade II and III tumours (*n*=20), 1p loss (*P*\<0.0003 and 0.008) and combined 1p/19q loss (*P*\<0.006 and 0.007) were strongly associated with oligodendroglial differentiation ([Figure 2A](#fig2){ref-type="fig"}).

Invasion in relation to tumour phenotype
----------------------------------------

All gliomas showed variable numbers of invasive tumour cells within the slice tissue ([Figure 3](#fig3){ref-type="fig"}). Specimens from tumours other than gliomas were noninvasive in the slice assay.

Grade IV tumours showed higher *D*~90~ and higher *C*~90~ than grade II and III tumours ([Figure 5](#fig5){ref-type="fig"}Figure 5*D*~90~ and *C*~90~ according to tumour grade (**A,B**) and tumour type (**C--F**). *D*~90~ and *C*~90~ were lower for grade II and III than for grade IV tumours (**A,B**), for grade II and III Ols than for grade II and III As (**C,D**); grade IV GOCs had lower *C*~90~ than grade IV GBMs (**F**), but the difference in *D*~90~ (**E**) was not significant (Mann--Whitney test).), mostly because of higher *C*~90~ values ([Figure 5B](#fig5){ref-type="fig"}), since *D*~90~ values overlapped partially ([Figure 5A](#fig5){ref-type="fig"}). When cases in the overlap zone in [Figure 5A](#fig5){ref-type="fig"} were separately examined, grade IV (*n*=12) still showed higher *C*~90~ than grade II and III (*n*=10) tumours: 94 (26--158) AUs *vs* 59 (19--121) AUs (*P*\<0.006). Grade II and grade III tumours were similarly invasive (data not shown).

Within the group of grade II and III tumours, *D*~90~ and *C*~90~ were lower for Ols and OlAs than for As ([Figure 5C, D](#fig5){ref-type="fig"}). Since oligodendroglial differentiation was highly predictive of 1p or 1p/19q loss, tumours harbouring these deletions also showed lower *D*~90~ and *C*~90~ than nondeleted tumours (data not shown). Within the group of grade IV tumours, *C*~90~ was lower for GOCs than for GBMs ([Figure 5F](#fig5){ref-type="fig"}), while the difference in *D*~90~ was not significant ([Figure 5E](#fig5){ref-type="fig"}).

This difference in *C*~90~ was largely due to different cell densities of invasion within 0.5 mm away from the implants. According to *C*~90~ in this zone, tumours could be subdivided into three patterns ([Figure 4](#fig4){ref-type="fig"}): high (200⩽*C*~90~⩽400 cells mm^−2^) (nine GBMs); intermediate (100⩽*C*~90~⩽200 cells mm^−2^) (five GBMs, three GOCs), and low (*C*~90~⩽100 cells mm^−2^) (three GOCs and the giant cell GBM).

The giant cell GBM, an unusually indolent tumour, which has not progressed for 2 years after biopsy and irradiation, was minimally invasive (*D*~90~=0.576 mm; *C*~90~=52 AU) and was excluded from further analyses.

Invasion in relation to histological features and 1p/19q loss in grade II and III gliomas
-----------------------------------------------------------------------------------------

*D*~90~ was inversely correlated with 1p/19q loss (*r*=−0.64; *P*\<0.002), cell density (*r*=−0.66; *P*\<0.0007), vessel density (*r*=−0.49; *P*\<0.03), and the MIB1/caspase 3 ratios (*r*=−0.45; *P*\<0.05), and positively correlated with proportion of diffuse areas (*r*=0.56; *P*\<0.007). 1p/19q loss was positively correlated with cell density and negatively with diffuse areas (*P*\<0.03). Cell or vascular density, and the MIB1/caspase 3 ratios were significantly positively associated among themselves (0.43\<*r*\<0.60), while the proportion of diffuse areas was significantly negatively correlated with cell density (*r*=−0.72), and the MIB1/caspase 3 ratios (*r*=−0.47). A correlation matrix revealed correlations in 12 out of 15 pairs, three factors were extracted that accounted for over 80% of the variance, communality was 0.79--0.89, sampling adequacy was 78%, and factor structure simplicity was satisfactory. Factors loadings ([Table 1](#tbl1){ref-type="table"} Table 1Factor loadings (only values ≫0.5 have been retained) resulting from the principal component analysis **Factor 1Factor 2Factor 3**Vessel density+0.92------Mib1/caspase 3+0.75------Diffuse areas---−0.89---Cell density---+0.87---*D*~90~------−0.741p/19q loss------+0.91[^1]) translated into three patterns of growth: 'vascular and *in situ* proliferative' (factor 1), 'hypercellular and compact (not diffuse)' (factor 2), and 'noninvasive, characteristic of tumours with 1p/19q loss (factor 3). Ols and OlAs had higher factor scores than As for all the three factors ([Figure 6](#fig6){ref-type="fig"}Figure 6Factor scores of grade II and III As and Ols for the principal components extracted ([Table 1](#tbl1){ref-type="table"}): 'vascular *in situ* proliferating' (factor 1), 'hypercellular and compact' (factor 2), and 'noninvasive, characteristic of tumours with 1p/19q loss' (factor 3). Score for all the three factors were higher for Ols than for As (Mann--Whitney test).). Thus, correlation analysis of invasiveness, *in situ* growth, and histological features suggests that grade II and III oligodendroglial tumours with 1p/19q loss may tend to grow *in situ* as more circumscribed and more vascular masses, in contrast to the more diffuse, infiltrative, and less bulky As.

*In vitro* infiltration and *in situ* growth
--------------------------------------------

The ratio MIB-1/caspase 3 LI increased progressively with grade ([Figure 7A](#fig7){ref-type="fig"}Figure 7MIB-1/caspase 3 ratios of gliomas of different grade (**A**) and type (**B,C**); three-dimensional plots -- MIB-1/caspase 3 ratio (*X*), D90 (*Y*), C90 (*Z*-axis) -- of grade II and III tumours (**D**) and grade IV tumours (**E**). (**A**) *In situ* proliferation increased with grade; (**B**) higher *in situ* proliferation potentials for Ols than for As and for GOCs than for GBMs were suggested for tumours studied in the invasion assay (Kruskal--Wallis test); (**C**) A larger series (*n*=69) confirmed that grade II and grade III Ols had higher MIB-1/caspase 3 ratios than As of the same grade (Mann--Whitney test); (**D**) factors that determine the growth pattern of gliomas delineate important differences between the invasive As and the *in situ* proliferating Ols (grade II and III). (**E**) Note that some GBMs have very low proliferative potentials, and presumably grow predominantly by infiltration: knowledge of the infiltrative potential of a glioma is probably as important as knowledge of its capacity to proliferate.), and tended to be higher for Ols and GOCs than for purely astrocytic tumours ([Figure 7B](#fig7){ref-type="fig"}). We examined this result in 32 additional grade II--IV gliomas selected from our files. Results obtained in this expanded series (*n*=69) confirmed that grade II and grade III Ols had higher MIB-1/caspase 3 LIs ratios than As ([Figure 7C](#fig7){ref-type="fig"}).

The MIB1/caspase 3 ratio (*X*), *D*~90~ (*Y*), and *C*~90~ (*Z*-axis) for each tumour were plotted separately for grade II and III ([Figure 7D](#fig7){ref-type="fig"}) and grade IV tumours ([Figure 7E](#fig7){ref-type="fig"}). This graphic analysis illustrated that infiltrative spread is predominant in grade II and III As, while *in situ* proliferation is predominant in Ols ([Figure 7D](#fig7){ref-type="fig"}). As documented in other studies ([Rhodes, 1998](#bib28){ref-type="other"}), some GBMs could have very low proliferative potentials ([Figure 7E](#fig7){ref-type="fig"}), and presumably grow predominantly by infiltration.

DISCUSSION
==========

The main result of the present study is that oligodendroglial tumours with 1p/19q loss were less invasive *in vitro* than astrocytomas without deletions on these chromosomes. Correlation analysis of parameters measured *ex vivo* suggested that *in vivo* Ols may present relatively compact and hypercellular *in situ* proliferating masses, in contrast to the more diffuse, less proliferative, and more invasive As.

The ratio between cell spread and *in situ* proliferation is relevant to describe how gliomas are organised in space ([Swanson *et al*, 2000](#bib33){ref-type="other"}, [2002](#bib34){ref-type="other"}). Three patterns of glioma spatial organisation have been defined: type I (solid bulk tumour), type II (solid tumour plus a diffuse halo of infiltrating cells), and type III structures (diffuse cloud of cells, no solid bulk) ([Kelly *et al*, 1987](#bib20){ref-type="other"}). The different ratios of infiltration and proliferation of grade II and III Ols and As demonstrated by multivariate analysis suggest that the spatial organisation of the less invasive Ols may correspond to type I or to type II with a limited diffuse component, while that of the more invasive As corresponds to more diffuse type II or to type III structures.

The *in vitro* invasion assay correlates to a large extent with aspects of glioma behaviour that are known to depend on the degree of invasion. For instance, the time to tumour progression after surgery (TTP) is thought to depend on the number of glioma cells infiltrating the resected margin which, in order to form a secondary growth, need to reach a critical cell density ([Chicoine and Silbergeld, 1995](#bib3){ref-type="other"}; [Burgess *et al*, 1997](#bib2){ref-type="other"}; [Silbergeld and Chicoine, 1997](#bib32){ref-type="other"}). An astrocytic (*vs* oligodendroglial or mixed) phenotype has been found to be highly predictive of shorter TTP in 379 grade II glioma patients ([Karim *et al*, 1996](#bib19){ref-type="other"}). Up to four times longer TTP was documented for 1p/19q codeleted Ols than for tumours without these deletions ([Fallon *et al*, 2004](#bib7){ref-type="other"}). Likewise, in a series of pure GBMs and GOCs, 90% of the patients with unusually long TTP had tumours with an oligodendroglial component ([Kraus *et al*, 2000](#bib22){ref-type="other"}). Besides the numbers of invading cells, TTP could be influenced by spatial patterns. Imaging methods detect tumour bulks of a certain minimal cell density (the threshold cell density concept) ([Burgess *et al*, 1997](#bib2){ref-type="other"}; [Swanson *et al*, 2000](#bib33){ref-type="other"}), and this bulk is the target of surgery. The more compact and cellular the tumour (e.g. type I), the greater the likelihood of a larger resection ([Swanson *et al*, 2002](#bib34){ref-type="other"}). Theoretically, tumour burden will remain greater post-surgery for diffuse hypocellular tumours (e.g. type III), since a smaller portion is identified and removed.

Patients with grade II and III Ols and OlAs have better prognosis than patients with As of the corresponding grade even in the absence of chemotherapy ([Karim *et al*, 1996](#bib19){ref-type="other"}; [Louis *et al*, 2001](#bib24){ref-type="other"}). Similarly, in several studies gliomas with grade IV histology and an oligodendroglial component have been associated with better prognosis than pure GBMs ([Donahue *et al*, 1997](#bib6){ref-type="other"}; [Kraus *et al*, 2000](#bib22){ref-type="other"}). There is a seeming contradiction between this evidence and results of comparative studies which have invariably documented higher proliferation ([Deckert *et al*, 1989](#bib5){ref-type="other"}; [Karamitopoulou *et al*, 1994](#bib18){ref-type="other"}; [Schiffer *et al*, 1995](#bib30){ref-type="other"}; [Gordower *et al*, 1998](#bib12){ref-type="other"}; [Heesters *et al*, 1999](#bib14){ref-type="other"}, [2002](#bib15){ref-type="other"}; [Geiger *et al*, 2000](#bib9){ref-type="other"}) and lower apoptotic rates ([Geiger *et al*, 2000](#bib9){ref-type="other"}; [Heesters *et al*, 2002](#bib15){ref-type="other"}) for Ols than for As of similar grade. Our results may help resolve this contradiction since models of glioma growth kinetics predict that growth by infiltration should be faster than growth by proliferation ([Burgess *et al*, 1997](#bib2){ref-type="other"}). The opposition, from a kinetic point of view, between infiltration and proliferation may also have important biological underpinnings. There is evidence that migrating cells do not proliferate ([Giese *et al*, 1996](#bib10){ref-type="other"}) because they downregulate genes involved in cell proliferation ([Mariani *et al*, 2001](#bib25){ref-type="other"}). The concomitant upregulation of antiapoptotic programmes ([Mariani *et al*, 2001](#bib25){ref-type="other"}; [Joy *et al*, 2003](#bib16){ref-type="other"}) indicates that these nondividing cells may also be longer-lived. This particular kinetic profile of migrating cells should be taken into account by models studying the relationships between the infiltration and proliferation determinants of glioma growth.

The threshold cell density concept also explains why aggressiveness of gliomas should depend on high densities rather than on long distances of cell invasion. Low-grade gliomas disseminate to considerable distances in the brain, Ols invade the brain cortex forming secondary structures such as perineuronal (satellitosis) and subpial cell accumulations ([Giese *et al*, 2003](#bib11){ref-type="other"}). If, however, invasion is of low (i.e. subthreshold) cell density, it would not result in clinical growth ([Burgess *et al*, 1997](#bib2){ref-type="other"}). Indeed, *D*~90~ values but not *C*~90~ values overlapped between grade IV and grade II and III tumours.

The incidence of 1p/19q loss reported here is in keeping with previous reports on GOCs ([Kraus *et al*, 2001](#bib23){ref-type="other"}) and 'classic' Ols showing cells with clear halos and typical branching vessels ([Sasaki *et al*, 2002](#bib29){ref-type="other"}, [Watanabe *et al*, 2002](#bib37){ref-type="other"}) -- 11 out of 13 grade II and III Ols and OlAs in this series contained area with these well-recognised features. 1p/19q codeleted classic Ols are associated with long survival ([Fallon *et al*, 2004](#bib7){ref-type="other"}) and tend to evolve indolently even without treatment ([van den Bent *et al*, 2003](#bib36){ref-type="other"}). Although tentatively, we speculate that this particular evolution may be due to limited infiltrative tumour growth. Ostensibly, the high proportion of 'classic' Ols\' in our series calls for a comparison with Ols devoid of classic features. We, however, did not attempt to make this comparison, given the poor consensus on the histological definition of these tumours, amply illustrated in the recent literature ([Fuller *et al*, 2003](#bib8){ref-type="other"}). Our results support the view that 'classic' Ols\' may be a distinct glioma entity characterised by high incidence of 1p/19q loss, limited invasive potential, and the kinetic profile of *in situ* proliferating, relatively circumscribed tumours.

In conclusion, we believe that our organotypic model of glioma invasion is a realistic tool providing information about the infiltrative potential of gliomas, a fundamental behavioural characteristic of these tumours, which has been difficult to analyse in quantitative terms.
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[^1]: Factor 1: vascular, *in situ* proliferative; Factor 2: hypercellular and compact (not diffuse); Factor 3: noninvasive, characteristic of tumours with 1p/19q loss.
